within Pharmacolibrary.Drugs.ATC.R;

model R06AX24
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0007,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.087,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R06AX24</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Epinastine is a second-generation antihistamine (H1 receptor antagonist) used primarily for the treatment of allergic conjunctivitis and, in some countries, allergic rhinitis. It is approved for topical ophthalmic use and is available in some markets, but not all.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult individuals; no peer-reviewed human pharmacokinetic publication was identified at time of report.</p><h4>References</h4><ol><li><p>Ogiso, T, et al., &amp; Tanino, T (2001). Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles. <i>Biological &amp; pharmaceutical bulletin</i> 24(7) 790–794. DOI:<a href=\"https://doi.org/10.1248/bpb.24.790\">10.1248/bpb.24.790</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11456119/\">https://pubmed.ncbi.nlm.nih.gov/11456119</a></p></li><li><p>Sarashina, A, et al., &amp; Igarashi, T (2005). Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. <i>British journal of clinical pharmacology</i> 59(1) 43–53. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2005.2250\">10.1111/j.1365-2125.2005.2250</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15606439/\">https://pubmed.ncbi.nlm.nih.gov/15606439</a></p></li><li><p>Tasaka, K (2000). Epinastine: An update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. <i>Drugs of today (Barcelona, Spain : 1998)</i> 36(11) 735–757. DOI:<a href=\"https://doi.org/10.1358/dot.2000.36.11.1136048\">10.1358/dot.2000.36.11.1136048</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12845334/\">https://pubmed.ncbi.nlm.nih.gov/12845334</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R06AX24;
